Skip to Main Content
Close Menu
About Us
Platform
Pipeline
Partnering
News
Careers
Contact Us
News Releases
Kallyope Announces License Agreement with Novo Nordisk
September 10th, 2024
Sosei Heptares and Kallyope Nominate First GPCR Target for Therapeutic Development in Gastrointestinal Diseases
November 10th, 2023
Kallyope Enters Phase 2 With First-in-class Oral Approach for the Treatment of Both Obesity and Type 2 Diabetes
September 27th, 2023
Kallyope Appoints Franz Humer, Ph.D., as Chair of its Board of Directors
June 6th, 2023
Kallyope Receives $8.2 Million Grant to Identify Novel Interventions for Children and Undernourished Pregnant Women and Mothers Experiencing Environmental Enteric Dysfunction
May 10th, 2023
Renowned Biopharma Leaders Join Newly Established Kallyope Clinical Development Advisory Board
August 5th, 2022
Kallyope and Brightseed Enter Collaboration to Identify and Validate Novel Plant-Based Bioactives
July 21st, 2022
Kallyope, Pioneers in Drug Discovery via the Gut-Brain Axis, Advances Discovery and Development Teams With New Appointments
July 6th, 2022
Sosei Heptares and Kallyope Enter Collaboration to Identify and Validate Novel Gastrointestinal GPCR Targets for Drug Discovery
May 17th, 2022
Kallyope, Pioneers in Drug Discovery via the Gut-Brain Axis, Adds New Chief Business Officer
April 25th, 2022
Kallyope, Pioneers in Drug Discovery via the Gut-Brain Axis, Strengthens Senior Leadership Team with Key Appointments
March 16th, 2022
Kallyope Raises $236M Series D Financing to Fuel Expansion of Novel Gut-Brain Axis Therapeutic Programs
February 15th, 2022
Kallyope Announces CEO Transition as Company Advances to its Next Stage of Growth
August 5th, 2021
Kallyope Inc. Appoints Patrick Flanigan as Chief Financial Officer
June 1st, 2021
Kallyope Inc. Announces $112M Series C Financing to Support First Clinical Trials and Advance Portfolio of Programs Targeting the Gut-Brain Axis
March 25th, 2020
Kallyope Inc. Appoints Peter Hecht to Board of Directors
February 20th, 2020
Kallyope Inc. Appoints Juha Lauren as Chief Business Officer
September 4th, 2019
Kallyope Inc. Appoints Brett Lauring as Chief Medical Officer
February 5th, 2019
Kallyope Inc. Announces $21 Million Expansion of Series B Financing
December 5th, 2018
Kallyope and Novo Nordisk Announce Collaboration to Discover Novel Therapeutics for Obesity and Diabetes
June 19th, 2018
